Plethora Solutions Holdings Plc Regulatory News (PLE)

10 Aug 2006 07:00

Plethora Solutions Holdings PLC10 August 2006 New head of clinical development Dr E. Versi appointed Senior Vice-President, Clinical Development Plethora Solutions Holdings PLC ("Plethora" or the "Company", AIM: PLE), thespecialist developer of products for the treatment and management of urologicaldisorders, is pleased to announce that it has appointed Dr Eboo Versi to theposition of Senior Vice-President, Clinical Development. Dr Versi is aspecialist in Phase II-IV clinical development and joins Plethora at a time whenthe Company has five development programmes moving through Phase II studies. Dr Versi is recognised globally as a leading figure in clinical development. Hebegan his commercial career with Pharmacia & Upjohn, later Pfizer as Director ofUrology and Women's Health before going on to be VP and Head of Medical Affairsat Yamanouchi and latterly Senior VP Medical Affairs at Odyssey Pharmaceuticals.His academic and clinical qualifications include a first degree and a doctoratefrom Oxford University and a medical degree from Cambridge University. Afterbecoming a Consultant in Obstetrics and Gynaecology in London, he moved to theUnited States to become Associate Professor at Harvard Medical School andDivision Chief in Obstetrics and Gynaecology at the Brigham and Women's Hospitaland Clinical Associate at Massachusetts General Hospital in Boston. Dr Versi iscurrently Clinical Associate Professor at the University of Medicine andDentistry of New Jersey. Steven Powell, CEO of Plethora, commented: "This appointment comes at a pivotal point in the evolution of our business. Wehave created a substantial product development pipeline focused on urologicaldisorders and over the next two years we will see a significant flow of clinicaldata as the pipeline matures. Dr Versi has the commercial experience and clinical expertise to support thesecompounds through their clinical and regulatory milestones before we licensethem out for Phase III development and marketing. His skills will provide asignificant contribution to the growth of our business." -Ends- For further information contact: Plethora Solutions Tel : 020 7269 8630Steven Powell City/Financial Enquiries Tel: 020 7379 5151MaitlandBrian Hudspith/Liz Morley/Wendy Timmons Scientific/Trade Press Enquiries Tel: 020 7861 3838 DeFacto Communications About Plethora: Plethora is focused on the development of products for the treatment andmanagement of urological disease. The Company has products in clinicaldevelopment for the treatment of overactive bladder, benign prostatichyperplasia, stress urinary incontinence, interstitial cystitis and prematureejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based TimmMedical Technologies Inc which markets products for the treatment of erectiledysfunction (ED) to urology clinics through a US-based speciality sales team.The Company is headquartered in the UK and is listed on the London StockExchange (AIM:PLE) Further information is available atwww.plethorasolutions.co.uk This information is provided by RNS The company news service from the London Stock Exchange